Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Extended release stimulant effective for long-term ADHD treatment

05.10.2005


Study finds no significant side effects in children treated up to two years



new study has found that an all-day, extended-release stimulant for treating attention-deficit hyperactivity disorder (ADHD) remains effective for up to two years without significant side effects. In the October issue of the Journal of the American Association of Child & Adolescent Psychiatry, a multi-institutional research team reports finding that treatment with Concerta, a once-daily form of the drug methylphenidate, successfully controlled ADHD symptoms in more than 200 children with ADHD. The study was supported by McNeil Pharmaceuticals, which manufactures Concerta.

"Although ADHD is recognized as a chronic disease, we’ve known very little about the effects of chronic treatment," says Timothy Wilens, MD, of the Massachusetts General Hospital (MGH) Pediatric Psychopharmacology Unit, lead author of the JAACAP report. "There have been concerns about whether the stimulant medications that are a mainstay of treatment continue to be effective, whether patients build up tolerance, or whether the drugs might have adverse effects on cardiovascular health or growth. This investigation sheds some important light on those questions."


The study initially enrolled more than 400 children, ages 6 to 13, who previously had participated in short-term, placebo-controlled trials of Concerta. In the new trial, all participants received the active medication at one of three dose levels. Dosage could be adjusted to improve effectiveness or reduce side effects. Participants’ height and weight, blood pressure, heart rate and other clinical measures were taken at regular intervals during the study period. The children’s parents and teachers were surveyed periodically regarding whether they believed treatment was effective in controlling ADHD symptoms

The entire, two-year study was completed by 229 participants, with others dropping out for a variety of reasons. Throughout the study period, measures of treatment effectiveness were consistent, with around 85 percent of parents and teachers reporting treatment results to be good or excellent. However, it was necessary to increase the children’s dose by about 25 percent during the study, with most increases happening during the first year. All the children grew at rates considered normal for their age, and they gained only slightly less weight than would have been expected. In general, there were no clinically significant effects on blood pressure, heart rate, or other cardiac measures.

"We found these medications do continue to be effective in the long-term. While some particicipants did need to increase dosage beyond what could be attributed to their growth, any tolerance that developed seemed to be slight and limited to the first year," says Wilens. "We haven’t seen any clinically meaningful problems with height and weight or any cardiovascular difficulties in this study, which also is the first to evaluate this kind of daylong treatment in a large group of children."

Wilens is an associate professor of Psychiatry at Harvard Medical School. The study’s co-authors are Keith McBurnett, PhD, University of California at San Francisco; Mark Stein, PhD, University of Chicago; Marc Lerner, MD, University of California at Irvine; Thomas Spencer, MD, MGH; and Mark Wolraich, MD, University of Oklahoma.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>